报价延迟最少15分钟:2025/07/25 13:47 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.93 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.74/-0.70
|
|
企业价值
94.31M
|
| 资产负债 |
|
每股账面净值
1.07
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
103.20K
|
|
每股收益
0.48
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/25 13:47 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline. |
